SEC Form 6-K filed by CASI Pharmaceuticals Inc.

11/15/24 8:30:25 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CASI alert in real time by email

6-K 1 tm2428584d1_6k.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE
13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2024

Commission File Number 001-41666

CASI PHARMACEUTICALS, INC.

(Translation of registrant’s name into English)

1701-1702, China Central Office Tower 1

No. 81 Jianguo Road, Chaoyang District

Beijing, 100025

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F x Form 40-F ¨

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release of CASI Pharmaceuticals, Inc. dated November 15, 2024

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CASI Pharmaceuticals, Inc.

	By:	/s/ Wei-Wu He
	Name:	Wei-Wu He
	Title:	Chairman & CEO

Date: November 15, 2024

Get the next $CASI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CASI

Date	Price Target	Rating	Analyst

More analyst ratings

$CASI
Market Insights

Live Market Insights

CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang has more than 30 years of experience as a physician scientist, investor, and biotech executive. He is a cardiologist by training from UCSF, followed by 20 years of investment experience as a portfolio manager at Farallon Capital and Chief Investment Officer at RS Investments Value Group. Most recently, he was the President of Athenex cell therapy division and led clinical deve
7/8/24 7:33:54 AM ET
$CASI
Biotechnology: Pharmaceutical Preparations
Health Care
CASI Pharmaceuticals shares are trading higher after the company announced plans to submit an Investigational New Drug application to the FDA for CID-103 for the treatment of antibody-mediated rejection in kidney transplant recipients. Also, the company received a preliminary non-binding proposal letter from CEO and Chairman Wei-Wu He to acquire its business operations in China.
6/27/24 8:49:52 AM ET
$CASI
Biotechnology: Pharmaceutical Preparations
Health Care
Market-Moving News for June 27th
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Proposal To Acquire Its China Business For Aggregate Purchase Price Of $40M MEDS: 34% | TRxADE HEALTH shares are trading higher. The company reported Q1 financial results. RXRX: -21% | Recursion Pharmaceuticals Announced The Pricing Of Its Underwritten Public Offering Of 30,769,230 Shares Of Its Class A Common Stock At A Price To The Public Of $6.50 Per Share
6/27/24 8:37:40 AM ET
$CASI
$MEDS
$RXRX
Biotechnology: Pharmaceutical Preparations
Health Care
Other Pharmaceuticals
Biotechnology: Biological Products (No Diagnostic Substances)

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024.Dr. Wei-Wu He, Chairman and CEO of CASI, said "The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company's strategic focus on the development for organ transplant rejection and autoimmune diseases. We just announced the Center for Drug Evaluation (CDE) of China's Nationa
11/15/24 8:00:00 AM ET
$CASI
Biotechnology: Pharmaceutical Preparations
Health Care
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
BEIJING, CHINA / ACCESSWIRE / October 24, 2024 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) to proceed with a phase 1/2 study of CID-103 in adults patients with chronic Immune Thrombocytopenia (ITP) in China. This China study is part of the global study that was approved by the US FDA in May 2024.CID-103 is a fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope that ha
10/24/24 8:00:00 AM ET
$CASI
Biotechnology: Pharmaceutical Preparations
Health Care
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
BEIJING, Sept. 4, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, at the Lotte New York Palace in New York City. Members of the CASI management team, including Chief Financial Officer Daniel Lang, MD, and Chief Medical Officer Alexander Zukiwski, MD, will host 1x1 investor meetings at the conference.
9/4/24 8:00:00 AM ET
$CASI
Biotechnology: Pharmaceutical Preparations
Health Care

Ligand Reports Second Quarter 2024 Financial Results
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
8/6/24 4:01:00 PM ET
$AGEN
$AMGN
$CASI
$LGND
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Ligand Reports First Quarter 2024 Financial Results
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe
5/7/24 4:00:00 PM ET
$AMGN
$CASI
$JAZZ
$LGND
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339
BEIJING, July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of the Assignment Agreement (the "Agreement") with Cleave Therapeutics, Inc. ("Cleave"), pursuant to which CASI obtained all rights and global intellectual property rights related to CB-5339, a novel VCP/p97 inhibitor, as well as all remaining CB-5339 drug substance and drug product. Additionally, CASI will assume responsibility of the United States ("US") CB-5339 Investigational New Drug ("IND") application.
7/20/23 8:00:00 AM ET
$CASI
Biotechnology: Pharmaceutical Preparations
Health Care